Autolus Therapeutics Azioni (NASDAQ: AUTL)

Ultime notizie per Autolus Therapeutics (NASDAQ:AUTL) Azioni

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

Nuveen California Dividend Advantage Municipal Fund 2

Trading Halt: Halted at 5:53:28 p.m. ET - Trading Halt: Halt News Pending

The two lucky turkeys this year, Peach and Blossom from Minnesota, escaped the hatchet when President Joe Biden pardoned them in the annual pre-Thanksgiving tradition at the White House Monday.
&#8220;This event marks the official start of the holiday season here in Washington,&#8221; Biden <a href="https://abcnews.go.com/Politics/peach-blossom-continue-white-house-turkey-tradition/story?id=116182776">said</a> to a crowd of 2,500 gathered on the South Lawn. &#8220;It&#8217;s also my last time to speak here as your president during this season and give thanks and gratitude. So let me say to you, it&#8217;s been the honor of my life. I&#8217;m forever grateful.&#8221;
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42173811/hemp-and-thanksgiving-from-the-mayflower-to-independence-the-crop-that-helped-build-a-nation">Hemp And Thanksgiving: From The Mayflower To Independence, The Crop That Helped Build A Nation</a>
<h1 class="wp-block-heading">Don't Forget Those Others You Promised To Pardon</h1>
It's been over two years since&nbsp;<a href="https://www.benzinga.com/topic/joe-biden" target="_blank" rel="noreferrer noopener">Biden</a>&#8216;s announcement to pardon all prior federal offenses&nbsp;<a href="https://www.benzinga.com/markets/cannabis/22/10/29175510/breaking-biden-announces-pardons-for-all-federal-marijuana-possession-convictions" target="_blank" rel="noreferrer noopener">of simple marijuana possession</a>. It must be pointed out that not one single person among the approximately 3,000 people incarcerated for federal cannabis offenses has been released.
To remedy that situation, the&nbsp;<a href="https://www.benzinga.com/topic/last-prisoner-project" target="_blank" rel="noreferrer noopener">Last Prisoner Project</a>&nbsp;(LPP) has a great idea for the soon-to-be-retired president: release those prisoners immediately. 
In its People Not Poultry project, the LPP is calling on Biden to free the thousands of non-violent cannabis prisoners still incarcerated for offenses that are now legal in more than half the country. Last week, the LPP joined a chorus of advocates and over 60 Congress members in&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/11/42122853/67-lawmakers-urge-biden-to-grant-clemency-to-people-still-in-jail-for-cannabis-offenses">sending a letter</a>&nbsp;to Biden seeking clemency so families can be reunited for the holidays.
In a press conference on the capitol steps, LPP Director of Strategic Initiatives Jason Ortiz, said, "Sadly, as of today, President Biden has given freedom to more turkeys than he has to people [incarcerated for cannabis]. This is a gross injustice and an injustice that President Biden can correct with a stroke of a&nbsp;pen."&nbsp;
<h1 class="wp-block-heading">Think Of Your Legacy, President Biden</h1>
&#8220;But time is running out for President Biden to use this power effectively," LPP wrote in a press statement shared with Benzinga in October. &#8220;As President Biden approaches the final months of his presidency, he has the unique opportunity to correct the injustices of the War on Drugs that he once helped champion. By commuting the sentences of those still incarcerated for cannabis, he can take a bold stand for justice, equity and healing.&#8221;
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42130001/green-wednesdays-biggest-weed-buyers-the-surprising-archetypes-driving-sales">Green Wednesday&#8217;s Biggest Weed Buyers: The Surprising Archetypes Driving Sales</a></li>
</ul>
Courtesy photo of National Turkey Federation with NTF chairman John Zimmerman and his son with President Joe Biden

Cannabis

Government

News

Legal

Joe Biden, How About Pardoning Non-Violent Cannabis Prisoners Along With Those Thanksgiving Turkeys?

Tigress Financial analyst Ivan Feinseth maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Buy and raises the price target from $96 to $103.

Price Target

Analyst Ratings

UBER

Tigress Financial Maintains Buy on Uber Technologies, Raises Price Target to $103

Legendary investor Warren Buffett has announced new charitable donations and updates to how his fortune will be spent after he is gone, news that comes months after he turned<a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig"> 94 years old.</a>
What Happened: Buffett announced Monday that he is converting 1,600 Berkshire Hathaway Class A (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shares into 2,400,000 Berkshire Hathaway Class B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shares to make new donations as part of his<a href="https://www.benzinga.com/startups/24/11/41866296/with-warren-buffett-donating-99-of-his-fortune-whats-left-for-his-three-children-well-its-complicated"> continued philanthropic efforts.</a>
Buffett is donating 1,500,000 Class B shares to The Susan Thompson Buffett Foundation and 300,000 shares to each of The Sherwood Foundation, The Howard G. Buffett Foundation and NoVo Foundation.
After the latest donation, Buffett will own 206,363 Class A shares, down 56.6% since his 2006 Giving Pledge.
Buffett recalled his belief and his late wife Susie's belief to support their children and philanthropic efforts in a new shareholder <a href="https://www.berkshirehathaway.com/news/nov2524.pdf">letter</a>.
"These bequests reflected our belief that hugely wealth parents should leave their children enough so they can do anything but not enough that they can do nothing," Buffett said. "Susie and I had long encouraged our children in small philanthropic activities and had been pleased with their enthusiasm, diligence and results."
Buffett said he is lucky to have lived as long as he has, while also recognizing his current age and the age of his children who are 71, 69 and 66.
"Father time always wins. But he can be fickle — indeed unfair and even cruel — sometimes ending life at birth or soon thereafter while, at other times, waiting a century or so before paying a visit."
Buffett said he never wished to create a family dynasty and trusts his children to pursue his wishes to continue philanthropic donations, along with successor trustees younger than his children.
"As such, three potential successor trustees have been designated. Each is well known to my children and makes sense to all of us."
Read Also: <a href="https://www.benzinga.com/general/education/24/10/41418702/warren-buffetts-words-of-wisdom-benzinga-readers-pick-their-favorite-oracle-of-omaha-quote">Warren Buffett&#8217;s Words Of Wisdom: Benzinga Readers Pick Their Favorite Oracle Of Omaha Quote</a>
Why It's Important: Buffett said friends question his strategies for donating his wealth and the instructions left for his children.
"I have one further suggestion for all parents, whether they are of modest or staggering wealth. When your children are mature, have them read your will before they sign it," Buffett said.
Buffett said it's important that children understand the logic of decisions and any responsibilities that they will take on after your death.
"You don't want your children asking "Why?" in respect to testamentary decisions when you are no longer able to respond."
Buffett recalls his life's success and early confidence that he could become rich.
"By not stepping on any banana peels, I now remain in circulation at 94 with huge sums in savings — call these units of deferred consumption — that can be passed along to others who were given a very short straw at birth."
The legendary investor said he lived his life the way he wanted by taking good care of his family and passing on wealth to others.
"With this philosophy, I have lived the way I wanted to live since my late 20s, and I have now watched my children grow into good and productive citizens."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/23/05/32270873/warren-buffett-shares-advice-on-succeeding-at-life-heres-how-your-obituary-could-be-involved">Warren Buffett Shares Advice On Succeeding At Life: Here&#8217;s How Your Obituary Could Be Involved</a></li>
</ul>
Photo: Shutterstock

Warren Buffett Announces New Charitable Gifts, Updates Plans For $150B Fortune: Billionaire Wants To Help Others 'Given A Very Short Straw At Birth'

The company said new data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally.

EXAS

Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS

Minnesota&#8217;s journey toward a recreational cannabis market hit a roadblock Monday when a local judge delayed the state's first lottery for cannabis business licenses.
The decision follows lawsuits filed by applicants who claim they were unfairly excluded from the process, <a href="https://www.startribune.com/minnesotas-first-lottery-for-cannabis-business-licenses-delayed-amid-litigation/601186596">reported</a> The Minnesota Star Tribune. 
Judge Stephen Smith ordered the state's Office of Cannabis Management (OCM) to postpone the Tuesday lottery for social equity applicants. The delay aims to provide the Court of Appeals time to address legal challenges raised by the rejected applicants.
The lottery is set to grant 282 social equity applicants pre-approval for cannabis business licenses. This move may impact the timeline for launching Minnesota's retail cannabis market.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/08/40149945/minnesota-cannabis-update-as-industry-prepares-to-launch-retail-sales"> Minnesota Cannabis Update As Industry Prepares To Launch Retail Sales</a>
<h3 class="wp-block-heading">Rejections Spark Lawsuits</h3>
Out of <a href="https://www.benzinga.com/markets/cannabis/24/08/40518244/minnesota-prepares-for-historic-social-equity-lottery-with-1-817-applications-for-280-cannabis-l">1,817 applicants</a>, 1,169 were denied entry into the lottery. The OCM cited failures to meet qualifying standards or submit proper documentation as reasons for rejection. However, rejected applicants argue the process lacked transparency and clarity.
Attorney Courtney Ernston, representing one of the plaintiffs, criticized the vague nature of rejection notices. "Simply saying the word ‘fail' is not a reason," Ernston said, adding that her client received no detailed explanation for her exclusion. Applicants and their legal representatives contend that the lack of transparency undermines their ability to contest or correct the rejections.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.
<h3 class="wp-block-heading">Implications For Minnesota's Cannabis Market</h3>
The delayed lottery raises concerns about potential setbacks in establishing <a href="https://www.benzinga.com/topic/minnesota-cannabis">Minnesota's</a> cannabis market.
The program&#8217;s social equity focus aims to prioritize individuals disproportionately affected by past cannabis prohibition, Gov. Tim Walz <a href="https://www.benzinga.com/markets/cannabis/24/02/37164553/gov-waltz-stresses-importance-of-social-equity-in-minnesotas-cannabis-market-marginalized-commun">pointed out</a> in an interview in February.
&#8220;Philosophically our goal is to make sure the equity piece was a big part of this. We certainly want to stay within the parameters of the law of who we can give help to. But I think the idea was, too often marginalized communities are left to the side. They&#8217;re left back,&#8221; Walz said.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40541485/exclusive-can-minnesota-keep-its-cannabis-industry-local-amid-out-of-state-pressure-legal-expert">EXCLUSIVE: Can Minnesota Keep Its Cannabis Industry Local Amid Out-Of-State Pressure? Legal Expert Weighs In</a></li>
</ul>
Cover: Photo by <a href="https://www.pexels.com/es-es/foto/vehiculos-en-la-carretera-cerca-de-edificios-altos-3859774/">Josh Hild</a> via Pexels

Regulations

Politics

Markets

Minnesota's Cannabis License Lottery Faces Legal Delays Over Rejections Dispute

BCYC

Bicycle Therapeutics Plans To Present Data At SABCS; Abstract Outlines Data Showing Enhanced Anti-Tumor Activity Of Zelenectide Pevedotin Monotherapy In Triple-negative Breast Cancer Patients With NECTIN4 Gene Amplification

Rumble Says Bitcoin Allocation Strategy Will Include Purchases, At Its  Discretion, Of Up To $20M

A major legal battle looms for Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) as the company prepares for an April trial, announced Monday, to face allegations from the U.S. Federal Trade Commission (FTC) over its acquisitions of <a href="https://www.benzinga.com/topic/meta">Instagram and WhatsApp.</a>
The FTC claims Meta strategically acquired the platforms in 2012 and 2014 to suppress competition in the social media space, accusations the company strongly denies, Reuters reports.
What Happened: The trial, set for April 14, comes after Judge James Boasberg rejected Meta's bid to dismiss the case. The FTC argues that Meta's actions have maintained its dominance in the social networking market at the expense of innovation and consumer choice. 
The lawsuit suggests that without the acquisitions, Instagram and WhatsApp could have evolved into independent competitors capable of challenging Meta's position.
Also Read: <a href="https://www.benzinga.com/24/11/42176317/exclusive-small-caps-hit-records-yet-russell-2000-is-still-very-discounted-relative-to-the-sp-500-expert-says">EXCLUSIVE: Small Caps Hit Records As Expert Says Russell 2000 &#8216;Still Very Discounted&#8217; Compared To S&amp;P 500</a>
The FTC filed its lawsuit in 2020, alleging that Meta violated antitrust laws by eliminating competition through its high-profile acquisitions. While Meta contends its investments have enhanced user experiences, the agency has expressed concerns over market consolidation and potential abuse of monopoly power. 
Judge Boasberg acknowledged the difficulties of applying traditional antitrust frameworks to evolving digital markets, stating, "The Commission faces hard questions about whether its claims can hold up in the crucible of trial." The judge also noted Meta's arguments regarding competition from platforms like TikTok and YouTube warrant examination during the proceedings.
Why It Matters: If the FTC succeeds in proving its case, it could set a precedent for tech industry antitrust enforcement, potentially reshaping the digital landscape. Meta's spokesperson argues that the acquisitions, which brought Instagram and WhatsApp under its umbrella, have significantly benefited users through improved services and accessibility.
The case builds on past regulatory concerns. The FTC recently alleged <a href="https://www.benzinga.com/news/24/06/39189663/mark-zuckerbergs-meta-withheld-key-details-in-instagram-and-whatsapp-acquisitions-ftc-claims">Meta withheld critical information</a> during its acquisition reviews, a claim supported by newly surfaced evidence. This follows earlier fines in Europe for similar issues surrounding the WhatsApp deal.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Tech

Meta Heads To Trial Over Instagram, WhatsApp Acquisitions

After factoring in estimated closing adjustments and new non-recourse project-level debt, the Company expects its total long-term corporate capital commitment to acquire the project to be approximately $70-75 million, which the Company expects to fund with existing sources of liquidity.
The Company expects the transaction to close in the first quarter of 2025, after which its targeted contribution to fiscal year 2025 results will be communicated.

CWEN

Clearway Energy Enters Binding Agreement To Acquire Operational Tuolumne Wind Project From Turlock Irrigation District

Earnings

Guidance

SUPV

Grupo Supervielle Q3 Net Income AR$8.9B; Confirm 15% ROE Guidance For FY2024

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera&#x2122;, Natera's competing product.&nbsp;

NTRA

Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

CHCI

Comstock Holding Says Carr Workplaces Signed New 26,331 Square Foot Lease At The Hartford In Arlington, Virginia

Shares of Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) traded higher on Monday in response to President-elect Donald Trump&#8217;s plans to nominate Marty Makary to lead the Food and Drug Administration (FDA). Here&#8217;s <a href="https://www.benzinga.com/quote/HIMS/news">what you need to know.</a>
What To Know: Market optimism surrounding Makary's selection may have bolstered Hims &amp; Hers shares on Monday as investors anticipate that the nomination could bring favorable regulatory changes to the sector. Makary is a proponent of telehealth and an executive at Sesame, a company that connects consumers to physicians who can prescribe compounded weight-loss drugs.
Hunterbrook Capital released a <a href="https://hntrbrk.com/hims-follow-up/">bullish report</a> on Monday announcing a long position in Hims &amp; Hers Health, citing potential benefits from Makary&#8217;s leadership at the FDA. The report suggests that Makary's background and expertise could stabilize the compounded GLP-1 drug market, in which Hims &amp; Hers Health is actively involved.
The report also highlighted regulatory challenges Hims &amp; Hers Health has faced, including fluctuating FDA guidance on <a href="https://www.benzinga.com/news/earnings/24/11/41718402/whats-going-on-with-hims-hers-health-stock-monday">drug shortages</a> and scrutiny over its prescribing practices. Makary's history with telehealth and compounded drugs may signal a more supportive regulatory environment, driving investor optimism.
Hims has been expanding into the weight-loss drug market with compounded GLP-1 products, which are cheaper alternatives to branded drugs like Wegovy and Mounjaro. Regulatory clarity under Makary's potential leadership is seen as a positive development for the company.
HIMS Price Action: Hims &amp; Hers shares closed Monday up 23.9% at $31.39, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png" alt="" class="wp-image-664105" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1.png 1468w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/11/42172722/gold-down-over-3-rigetti-computing-shares-spike-higher">Gold Down Over 3%; Rigetti Computing Shares Spike Higher</a></li>
</ul>
Image: Mohamed Hassan from Pixabay

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Hims & Hers Health Stock Monday?

HSAI

Hesai Group Expects Q4 Net Revenues To Approach $100M

Agora Expects Q4 Total Revenues To Be $34M - $36M, Also Expects Significant Improvement In Net Income / (Loss)

Hesai Q3 Adj EPS $(0.05) Misses $(0.02) Estimate, Sales $76.87M Beat $69.82M Estimate

For NBC, big balloons mean a bigger budget.
What Happened: The Macy's Thanksgiving Day Parade, known for its extravagant performances and cartoon character floats, is getting pricier. 
Since 1953, the peacock-branded network has aired the iconic turkey-day tradition. And, according to <a href="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=hp_lead_pos5">The Wall Street Journal</a>, NBC is considering a $60-million agreement — triple the current $20 million rate — to secure those rights through the next decade. 
See Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
So why the hefty price? Consider the appeal of live events in a streaming-dominated world. 
Comcast Corp.-owned (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) NBC and other traditional forms of TV are struggling to keep audiences after the whole cord-cutting trend. Marquee moments like parades, football games, boxing matches and awards shows are now popping up streaming services.
For NBC, the bet is that Peacock streaming customers will tune into the Nov. 28 crowd-pleaser, which is expected to feature celebrity appearances and live Broadway performances. 
Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) can relate. The Burbank, California-based conglomerate shelled out a 20% premium to swipe the Grammy Awards from Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), which had been airing it on CBS.
Why It Matters: The value of a live audience is as buoyant as a giant Snoopy balloon.
Nearly 30 million viewers tuned in to watch last year's parade, and this Thursday morning promises another spectacle of at least 11 marching bands, 28 clown crews, 22 balloons and 33 floats.
As for performers, viewers can expect a lineup of famous faces, including Charli D'Amelio, original &#8220;Wicked&#8221; star Idina Menzel, &#8220;Tonight Show&#8221; host Jimmy Fallon with The Roots, Coco Jones, Liza Colón-Zayas, The Temptations, T-Pain and the New York Liberty.
The route stretches 2.5 miles. It begins at 77th Street and Central Park West and winds its way down to Macy's Herald Square, the flagship store of Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>).
For those in New York City eager to preview the parade prep, the balloon inflation event happens Wednesday, Nov. 27, on the Upper West Side — a chance to get up close and personal with the towering inflatable icons.
Per <a href="https://www.usatoday.com/story/entertainment/tv/2024/11/21/macys-thanksgiving-day-parade-2024/76454992007/">USA Today</a>, this year&#8217;s event will debut new balloons, including Minnie Mouse, the Extraordinary Noorah and Gabby from Gabby&#8217;s Dollhouse.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">Macy&#8217;s Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips</a></li>
</ul>
Photo: Shutterstock

Entertainment

Events

Media

CMCSA

PARA

PARAA

Peacock Pays Up: Macy's Thanksgiving Parade Costs Set To Balloon For Content-Hungry NBC

Faraday Future plans to announce the date and detailed plan for the stock ticker symbol change in January 2025.
 &nbsp;

FFIE

Faraday Future Plans To Change its Stock Ticker Symbol From 'FFIE' To 'FFAI' In Early 2025

Agora Q3 EPADS $(0.26) Down From $(0.23) YoY, Sales $31.6M Down From $35.0M YoY

Autolus estimates that, with its current cash and cash equivalents, it is well capitalized to drive the full launch and commercialization of obe-ce...

Autolus estimates cash to drive full launch, commercialization of obe-cel

Jefferies analyst Kelly Shi maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $13.00. The co...

Jefferies Reaffirms Their Buy Rating on Autolus Therapeutics (AUTL)

Autolus Therapeutics ( ($AUTL) ) has provided an announcement. Autolus Therapeutics has achieved a pivotal milestone with the FDA's approval of AUC...

Autolus Therapeutics Wins FDA Approval for AUCATZYL®

Autolus Therapeutics ( ($AUTL) ) has provided an update. Autolus Therapeutics plc has achieved FDA approval for AUCATZYL&#xAE;, a treatment for relapsed...

Autolus Therapeutics Gains FDA Approval for AUCATZYL®

Autolus Therapeutics plc 2024 Q3 - Results - Earnings Call Presentation

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

Redburn Atlantic upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with an unchanged price target of $13. One week earlier than expected, Au...

Autolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic

Autolus Therapeutics (AUTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rajan Sharma fr...

Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated

Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset ...

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

AUTL

GILD

NVSEF

Health Care

Press Releases

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Management

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

General

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Comments

Autolus Therapeutics

Notizie

Ultime notizie per Autolus Therapeutics (NASDAQ:AUTL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO